Replies to post #236616 on Amarin Corp Plc (AMRN)

[ggwpq]

Omega-3s vs Pure EPA in Clinical Practice: What Do CV Outcomes Trials Tell Us?

Authors: P. Gabriel Steg, MD; Deepak L. Bhatt, MD, MPH; Matthew J. Budoff, MD; William S. Weintraub, MD

https://www.medscape.org/viewarticle/922880

[jfmcrr]

My theory is that Joe is Tom Waits...

Tom is less than a year older than me, but he would pass for 10 years older. There's a lot to be said for wide eyed innocentocity and a puritious body and mind lifestyle like mine.

I'm not Fred Neil

nor am I Tom Lehr.

But I try to be good company.

Speaking of which, I'm pretty levered up in AMRN, dodging vanilla margin calls on too many shares with well in the money calls for leverage and some respite from day to day margin concerns. Instead, there has been the bogeyman of an ADCOM, a delayed ADCOM, MO questions, CP's, the possibility of DDI MO testing, patent lawsuits, and other possible time delays eating at the position. Some of these have come to pass, and are now in the past, and I've rolled the calls out of harm's way as they occurred. It seems one last significant one is hanging fire and I look forward to the surcease of anxiety when the gavel falls. I'm mildly surprised given the likelihood that we will sail past this one, how much it still weighs on me.

Onward to LV 2, be it in Atlantic City or New Orleans, See ya there.